Wearable data-analytics startup VivoSense scored $25 million in a Series A funding round co-led by Perceptive Xontogeny Ventures (PXV) Fund and Debiopharm Innovation Fund. 

The Newport Beach, Calif.-based company helps stakeholders integrate wearable sensors into clinical trials to help monitor digital biomarkers. The company has software called VivoSense, which helps interpret sensor data for research and patient care. 

"This strategic investment from the Debiopharm Innovation Fund and the Perceptive Xontogeny Venture (PXV) Fund will allow VivoSense to accelerate the development of real-world digital clinical measures from wearable and remote-monitoring technologies,” Dudley Tabakin, CEO of VivoSense, said in a statement. “Measures that are trusted and valued by all stakeholders are the foundation on which all other innovation in digital health must be based. VivoSense is working to realize the potential of novel measures and technologies in regulatory and medical decision-making to leverage real-world data at scale, bringing life-saving treatments to the patients who need them most.”

Others raising capital include AI-backed neurological-disease diagnostic Altoida, which has snapped up an additional $14 million in a Series A extension round led by M Ventures and Whitecap Venture Partners. This new infusion of cash tops off their total Series A raise at $20.3 million. 

The brain-health company uses AI, machine learning and augmented reality to help collect cognitive biomarkers for neurological-disease detection. The data capture on the platform can be used to help fuel research and care for individuals with cognitive disorders. 

The Washington-based startup plans to use the new cash to help drive its research and grow its product development. The company also plans to commercialize its product in the U.S. and in global markets. 

"Altoida’s platform is the first to use augmented reality as the framework to simulate activities of daily living, and to leverage AI to develop scientifically-validated neurological disease diagnostics," Travis Bond, CEO of Altoida, said in a statement. "We are pleased to have new investors join Altoida and to have our existing investors continue their support. Having both biotech and tech industry investors with complementary acumen, networks and commitment to innovation in neurology will help enable us to bring our products to patients, providers and researchers earlier."

Also raising money is health tech company Zephyr AI, which announced an $18.5 million seed funding round. Lerner Group Investments llC and M-Cor Holdings led the funding round, with participation from Allen Y. Chao, AME Cloud Ventures, BoxGroup, MedStar Health, Roger W. Ferguson, Steve Oristaglio, Verily and other strategic investors.

The company uses artificial intelligence and big data to help fuel drug-discovery research and precision-medicine efforts. 

“This significant capital raise will help us expand our scope, including curating additional healthcare datasets, refining advanced machine-learning models and deriving actionable insights for better outcomes in patient care and drug discovery," David L. Morgan, CEO of Zephyr AI, said in a statement.